{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:54:44Z","timestamp":1792083284214,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","award":["IS-BRC-1215-200074"],"award-info":[{"award-number":["IS-BRC-1215-200074"]}],"id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","award":["08229"],"award-info":[{"award-number":["08229"]}],"id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.gim.2024.101172","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:46:48Z","timestamp":1717415208000},"page":"101172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D. Gareth","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma R.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5182","key":"10.1016\/j.gim.2024.101172_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A\u00a0strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"6559","key":"10.1016\/j.gim.2024.101172_bib2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.gim.2024.101172_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"20","key":"10.1016\/j.gim.2024.101172_bib4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.gim.2024.101172_bib5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jnci\/91.14.1241","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer","volume":"91","author":"Warner","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.gim.2024.101172_bib6","first-page":"741","article-title":"Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study","volume":"8","author":"Hopper","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15","key":"10.1016\/j.gim.2024.101172_bib7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8899","key":"10.1016\/j.gim.2024.101172_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.gim.2024.101172_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.gim.2024.101172_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jmedgenet-2014-102336","article-title":"Long-term prospective clinical follow-up after BRCA1\/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies","volume":"51","author":"Evans","year":"2014","journal-title":"J\u00a0Med Genet"},{"issue":"23","key":"10.1016\/j.gim.2024.101172_bib11","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.gim.2024.101172_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.27839","article-title":"The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling","volume":"119","author":"Vencken","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gim.2024.101172_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","article-title":"Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted?","volume":"145","author":"McGee","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gim.2024.101172_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.gim.2024.101172_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","article-title":"Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients","volume":"147","author":"Byrski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.gim.2024.101172_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.gim.2024.101172_bib17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jmg-2022-108790","article-title":"Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers","volume":"60","author":"Evans","year":"2023","journal-title":"J\u00a0Med Genet"},{"issue":"13-14","key":"10.1016\/j.gim.2024.101172_bib18","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1111\/jocn.16498","article-title":"Breast cancer genetic mutation: synthesis of women\u2019s experience","volume":"32","author":"McNamara","year":"2023","journal-title":"J\u00a0Clin Nurs"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360024001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360024001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:46:36Z","timestamp":1778798796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360024001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1098360024001060"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2024.101172","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2024.101172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"101172"}}